The Nasal Drug Delivery market has seen remarkable patterns as of late, reflecting a change in perspective in drug organization techniques. This painless methodology offers benefits like fast drug absorption, further developed bioavailability, and patient comfort.
Drug organizations are progressively putting resources into nasal drug delivery advances because of the potential for upgraded helpful results. This interest is driven by the capacity of nasal delivery to sidestep the gastrointestinal parcel and liver digestion, bringing about higher drug concentrations in the circulation system.
The pervasiveness of chronic diseases, including respiratory issues like asthma and chronic obstructive pulmonary disease (COPD), has powered the demand for compelling nasal drug delivery frameworks. This pattern is supposed to endure as the worldwide burden of chronic diseases keeps on rising.
There is a developing emphasis on creating nasal drug delivery arrangements custom-made to the novel necessities of pediatric and geriatric patients. Nasal organization gives a practical option in contrast to these populations, offering a safe course that is often more passable than customary strategies.
The market has seen a deluge in demand for nasal drug delivery frameworks for the management of sensitivities and rhinitis. Nasal sprays containing allergy medicines and corticosteroids are acquiring importance as viable answers for alleviating nasal side effects related with these conditions.
The reusing and reformulation of existing drugs for nasal delivery are getting momentum. This approach considers the expansion of patent life and the presentation of further developed adaptations of deep-rooted prescriptions through nasal organization.
The nasal drug delivery market is turning out to be progressively globalized, with organizations expanding their span to undiscovered markets. The emphasis on arising economies, where healthcare foundation is advancing, presents amazing open doors for market growth.
Progresses in genomics and personalized medicine have affected the advancement of custom fitted nasal drug delivery arrangements. Individualized treatment plans in view of genetic elements are driving the customization of nasal drug definitions for ideal supportive results.
Nasal Drug Delivery Market Overview
The nasal drug delivery market was valued at USD 52,998.5 million in 2018 and is projected to reach USD 81.1 Billion at 7.4% CAGR during the forecaast period 2023-2032.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new technological nasal drug delivery devices, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. Â
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the market growth.Â
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. Â
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.By Drug Type
By Dosage Form
By Basis of System
By Delivery Technologies
By Application
By End User
By Region
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)